Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 6/2011

01-06-2011 | Review

Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies

Author: Joerg-Patrick Stübgen

Published in: Journal of Neurology | Issue 6/2011

Login to get access

Abstract

The cytokine, tumor necrosis factor alpha (TNFα), has been implicated in many aspects of immune system development, immune response regulation, and T cell-mediated tissue injury. TNFα plays a less well-defined role in the pathogenesis of the idiopathic inflammatory myopathy (IIM) group of disorders, and has been considered a potential therapeutic target. Observational studies of TNFα-blockade in (mostly refractory) IIM have yielded inconsistent beneficial results so that administration of these biological agents is presently deemed an unreliable alternative treatment strategy. Moreover, anti-TNFα therapy has the rare potential to trigger myositis in patients with rheumatoid arthritis, hinting at a pre-existing “overlap disorder”. The full potential of TNFα-antagonism will be realized only if randomized controlled trials ascertain appropriate treatment regimens and identify patient subgroups most likely to benefit from such therapy.
Literature
1.
Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF (1998) Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 24:73–79PubMedCrossRef
2.
Figarella-Branger D, Civate M, Bartoli C, Pellissier JF (2003) Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 28:659–682PubMedCrossRef
3.
Salomonsson S, Lundberg IE (2006) Cytokines in idiopathic inflammatory myopathies. Autoimmunity 39:177–190PubMedCrossRef
4.
Cope A, Ettinger R, McDevitt H (1997) The role of TNF-α and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 148:307–312PubMedCrossRef
5.
Kollias G, Douni E, Kassiotis G, Kontoyiannis D (1999) The role of tumor necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Ann Rheum Dis 58(Suppl):32–39CrossRef
6.
Robinson WH, Genovese MC, Moreland LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44:1977–1983PubMedCrossRef
7.
Goetz FW, Planas JV, Mackenzie S (2004) Tumor necrosis factors. Dev Comp Immunol 28:287–297CrossRef
8.
Idriss HT, Naismith J (2000) TNF alpha and the TNF receptor superfamily: structure–function relationship(s). Microsc Res Tech 50:184–195PubMedCrossRef
9.
MacEwan DJ (2002) TNF receptor subtype signaling: differences and cellular consequences. Cell Signal 14:477–492PubMedCrossRef
10.
Slowik MR, De Luca LG, Fiers W, Pober JS (1993) Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am J Pathol 143:1724–1730PubMed
11.
Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W (1993) Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 177:1277–1286PubMedCrossRef
12.
Barbara JA, Smith WB, Gamble JR, Van Ostade X, Vandenabeele P, Tavernier J, Fiers W, Vadas MA, Lopez AF (1994) Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants. EMBO J 13:843–850PubMed
13.
Holtmann MH, Neurath MF (2004) Differential TNF-signaling in chronic inflammatory disorders. Curr Mol Med 4:439–444PubMedCrossRef
14.
Mukai Y, Shibata H, Nakamura T, Abe Y, Nomura T, Taniai M, Ohta T, Ikemizu S, Nakagawa S, Tsunoda S, Kamada H, Yamagata Y, Tsusumi Y (2009) Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J Mol Biol 385:1221–1229PubMedCrossRef
15.
Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, Spiegelman BM (1994) Altered gene expression for tumor necrosis factor-alpha and its receptor during drug and dietary modulation of insulin resistance. Endocrinology 134:264–270PubMedCrossRef
16.
Chabaud M, Fossiez F, Taupin JL, Miossec P (1998) Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 161:409–414PubMed
17.
Nagaraju K, Raben N, Merritt G, Loeffler L, Kirk K, Plotz P (1998) A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 113:407–414PubMedCrossRef
18.
Seko Y, Matsuda H, Kato K, Hashimoto Y, Yagita H, Okumura K, Yazaki Y (1993) Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackie virus B3. J Clin Invest 91:1327–1336PubMedCrossRef
19.
Michaelis D, Goebels N, Hohlfeld R (1993) Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am J Pathol 143:1142–1149PubMed
20.
De Bleecker JL, Engel AG (1994) Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 53:369–376PubMedCrossRef
21.
Moser B, Wolf M, Waltz A, Loetscher P (2004) Chemokines: multiple levels of leukocyte migration control. Trends Immunol 25:75–84PubMedCrossRef
22.
ENBREL (etanercept) (2007) Current prescribing information. In: Physicians’ desk reference. Thompson, Montvale, pp 584–591
23.
HUMIRA (adalimumab) (2007) Current prescribing information. In: Physicians’ desk reference. Thompson, Montvale, pp 466–471
24.
Page G, Chevrel G, Miossec P (2004) Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum 50:199–208PubMedCrossRef
25.
Scheurich P, Thoma B, Ucer U, Pfizenmaier K (1987) Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol 138:1786–1790PubMed
26.
Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, Probert L, Kollias G, McDevitt HO (1997) Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 185:1573–1584PubMedCrossRef
27.
28.
Limaye VS, Blimbergs P, Roberts-Thomson PJ (2009) Idiopathic inflammatory myopathies. Intern Med J 39:179–190PubMedCrossRef
29.
30.
Khanna S, Reed AM (2010) Immuno pathogenesis of juvenile dermatomyositis. Muscle Nerve 41:581–592PubMedCrossRef
31.
Mammen AL (2010) Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 1184:134–153PubMedCrossRef
32.
Amato AA, Barohn RJ (2009) Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 80:1186–1193PubMedCrossRef
33.
Greenberg SA (2010) Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep 12:221–228PubMedCrossRef
34.
Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T (2000) Elevation of serum soluble tumor necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol 19:352–359PubMedCrossRef
35.
Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G (2000) Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 99:585–588PubMedCrossRef
36.
Kuru S, Inukai A, Kato T, Liang Y, Kimura S, Sobue G (2003) Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol (Berl) 105:217–224
37.
De Bleecker JL, Meire VI, Declerq W, Van Aken EH (1999) Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 9:239–246PubMedCrossRef
38.
Peterson JM, Feeback KD, Baas JH, Pizza FX (2006) Tumor necrosis factor-alpha promotes the accumulation of neutrophils and macrophages in skeletal muscle. J Appl Physiol 101:1394–1399PubMedCrossRef
39.
Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC (2008) Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle. Brain 131:1228–1240PubMedCrossRef
40.
Gallucci S, Provenzano C, Mazzarelli P, Scuderi F, Bartoccioni E (1998) Myoblasts produce IL-6 in response to inflammatory stimuli. Int Immunol 10:267–273PubMedCrossRef
41.
Chen SE, Jin B, Li YP (2007) TNF-alpha regulates myogenesis and muscle regeneration by activating p38 MAPK. Am J Physiol Cell Physiol 292:1660–1671CrossRef
42.
Langen RC, van der Velden JL, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM (2004) Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J 18:227–237PubMedCrossRef
43.
Lecker SH, Solomon V, Mitch WE, Goldberg AL (1999) Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 129(Suppl 1):227–237
44.
Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87:2095–2147PubMed
45.
Tracey KJ, Lowry SF, Beutler B, Cerami A, Albert JD, Shires GT (1986) Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential. J Exp Med 164:1368–1373PubMedCrossRef
46.
Lee MD, Zentella A, Vine W, Pekala PH, Cerami A (1987) Effect of endotoxin-induced monokines on glucose metabolism in the muscle cell line L6. Proc Natl Acad Sci USA 84:2590–2594PubMedCrossRef
47.
Flores EA, Bistrian BR, Pomposelli JJ, Dinarello CA, Blackburn GL, Istfan NW (1989) Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. J Clin Invest 83:1614–1622PubMedCrossRef
48.
Goodman MN (1991) Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol 260:E727–E730PubMed
49.
Garcia-Martinez C, Agell N, Llovera M, Lopez-Soriano FJ, Argiles JM (1993) Tumor necrosis factor-alpha increases the ubiquitinization of rat skeletal muscle proteins. FEBS Lett 323:211–214PubMedCrossRef
50.
Reid MB, Li YP (2001) Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res 2:269–271PubMedCrossRef
51.
Reid MB, Lannergren J, Westerblad H (2002) Respiratory and limb muscle weakness induced by tumor necrosis factor alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med 166:479–484PubMedCrossRef
52.
Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, Chen EH (2000) TNFalpha-308 allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 43:2368–2377PubMedCrossRef
53.
Pachman LM, Fedczyna TO, Lechman TS, Lutz J (2001) Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity. Curr Rheumatol Rep 3:379–386PubMedCrossRef
54.
Werth VP, Callen JP, Ang G, Sullivan KE (2002) Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol 119:617–620PubMedCrossRef
55.
Hassan AB, Nikitina-Zake L, Sanjeevi CB, Lundberg IE, Padyukov L (2004) Association of the proinflammatory haplotype(MICA5.1/TNF2/TNFα2/DRB1*03) with polymyositis and dermatomyositis. Arthritis Rheum 50:1013–1015PubMedCrossRef
56.
Hassan AB, Fathi M, Dastmalchi M, Lundberg IE, Padyukov L (2006) Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis. J Autoimmun 27:62–68PubMedCrossRef
57.
58.
REMICADE (infliximab) (2007) Current prescribing information. In: Physicians desk reference. Thompson, Montvale, pp 971–979
59.
Efthimiou P (2006) Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiological and therapeutic implications. Semin Arthritis Rheum 36:168–172PubMedCrossRef
60.
Hengstman G, van den Hoogen F, van Engelen B, Barrera P, Netea M (2000) Anti-TNF-blockade with infliximab (Remicade®) in polymyositis and dermatomyositis. Arthritis Rheum 43:S193
61.
Saadeh CK (2000) Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractive to conventional therapy including steroid and other disease modifying agents. Arthritis Rheum 43:S193
62.
Singh R, Cuchacovich R, Huang W, Espinoza LR (2001) Inclusion body myositis unresponsive to etanercept. J Clin Rheumatol 7:279–280PubMedCrossRef
63.
Roddy E, Courtney PA, Morris A (2002) Non-Hodgkin’s lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology 41:1194–1195PubMedCrossRef
64.
Sprott H, Glatzel M, Michel BA (2004) Treatment of myositis with etanercept (Enbrel®), a recombinant human soluble fusion protein of TNF-α type II receptor and IgG1. Rheumatology 43:524–526PubMedCrossRef
65.
Laboiche I, Liozon E, Weschler B, Loustaud-Ratti P, Soria P, Vidal E (2004) Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology 43:532–533CrossRef
66.
Uhtman I, El-Sayad J (2004) Refractory polymyositis responding to infliximab. Rheumatology 43:1198–1199CrossRef
67.
Korkmaz C, Temiz G, Çetinbas F, Büyükkidan B (2004) Case report: successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha. Rheumatology 43:938–939CrossRef
68.
Selva-O’Callaghan A, Martînez-Costa X, Solans-Laque R, Mauri M, Capdevila JA, Vilardell-Tarrés M (2004) Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology 43:1197–1198CrossRef
69.
Marie I, Heliot P, Roussel F, Hervé F, Muir JF, Levesque H (2005) Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology 44:1202–1203CrossRef
70.
Anandacoomarasamy A, Howe G, Manolios N (2005) Advanced refractory polymyositis responding to infliximab. Rheumatology 44:562–563PubMedCrossRef
71.
Dold S, Justiniano ME, Marquez J, Espinoza LR (2007) Treatment of early and refractory dermatomyositis with infliximab: a report of 2 cases. Clin Rheumatol 26:1186–1188PubMedCrossRef
72.
Wendling D, Prati C, Ornetti P, Toussirot E, Streit G (2007) Anti TNF-alpha treatment of a refractory polymyositis. Rev Med Interne 28:194–195PubMedCrossRef
73.
Choi KH, Yoo WH (2009) Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis. Rheumatol Int 29:463–466PubMedCrossRef
74.
Hill CL, Zhang Y, Sigurgeirsson B, Pukkula E, Mellemkjaer L, Airio A, Evans SR, Felson DT (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population based study. Lancet 357:96–100PubMedCrossRef
75.
Marie I, Hachulla E, Chérin P, Hellot MF, Herson S, Levesque H, Hatron PY (2005) Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 53:155–165PubMedCrossRef
76.
Efthimiou P, Schwartzman S, Kagen LJ (2006) Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of 8 patients. Ann Rheum Dis 65:1233–1236PubMedCrossRef
77.
Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G (2006) Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33:1802–1804PubMed
78.
Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA (2008) Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 47:877–880PubMedCrossRef
79.
Vandenbroucke JP (2001) In defense of case reports and case series. Ann Intern Med 134:330–334PubMed
80.
Noordzij M, Dekker FW, Zoccali C, Jager KJ (2009) Study design in clinical research. Nephron Clin Pract 113:c218–c221PubMedCrossRef
81.
Jenicek M (1999) Clinical case reporting in evidence-based medicine. Butterworths, Oxford, p 1999
82.
Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, Mendell JR (2006) Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 66(Suppl 1):S123–S124PubMed
83.
Hengstman GJ, de Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN, Slott Jensen H, van Engelen BG, van den Hoogen FH (2008) Open-label trial of anti-TNF-α in dermatomyositis and polymyositis treated concomitantly with methotrexate. Eur Neurol 59:159–163PubMedCrossRef
84.
Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, van Engelen BG (2003) Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 50:10–15PubMedCrossRef
85.
Hengstman GJ, van den Hoogen FH, van Engelen BG (2004) Treatment of dermatomyositis and polymyositis with anti-tumor-necrosis factor-α: long-term follow-up. Eur Neurol 52:61–63PubMedCrossRef
86.
Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, Elvin K, Crow MK, Nennesmo I, Lundberg IE (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67:1670–1677PubMedCrossRef
87.
Ramos-Casals M, Brito-Zeron P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86:242–251CrossRef
88.
Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22:847–861PubMedCrossRef
89.
Borrås-Biasco J, Navarro-Ruiz A, Borrås C, Casterå E (2009) Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J 102:1133–1140CrossRef
90.
Wetter DA, Davis MD (2009) Lupus-like syndrome attributable to anti-tumor necrosis factor therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 84:979–984PubMedCrossRef
91.
Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA, BIOGEAS Study Group (2010) Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 9:188–193PubMedCrossRef
92.
Mohan N, Edwards ET, Cupps TR, Oliviero PJ, Sandberg G, Crayton H, Richert JR, Siegel JN (2001) Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritis. Arthritis Rheum 44:2862–2869PubMedCrossRef
93.
Tristano AG (2010) Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. J Neurol 257:1421–1431PubMedCrossRef
94.
95.
Musial J, Undas A, Celinska-Lowenhoff M (2003) Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) 42:1566–1568CrossRef
96.
Urata Y, Wakai Y, Kowatari K, Nitobe T, Mizushima Y (2006) Polymyositis associated with infliximab treatment for rheumatoid arthritis. Mod Rheumatol 16:410–411PubMedCrossRef
97.
Hall HA, Zimmermann B (2006) Evolution of dermatomyositis during therapy with a tumor necrosis factor α inhibitor. Arthritis Rheum 15:982–984CrossRef
98.
Liozon E, Outtara V, Loustaud-Ratti V, Vidal E (2007) Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma. Scand J Rheumatol 36:484–486PubMedCrossRef
99.
Vordenbaumen S, Neuen-Jacob E, Richter J, Schneider M (2010) Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFα and rituximab. Clin Rheumatol 29:555–558PubMedCrossRef
100.
Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ (2004) The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 126:19–31PubMedCrossRef
101.
Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, Mayes MD, Varga J, Medsger TA Jr, Love LA (2000) Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 43:243–249PubMedCrossRef
102.
Pitkeathly DA, Coomes EN (1966) Polymyositis in rheumatoid arthritis. Ann Rheum Dis 25:127–132PubMed
103.
Targoff IN (2002) Idiopathic inflammatory myopathy: autoantibody update. Curr Rheum Rep 4:434–441CrossRef
Metadata
Title
Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies
Author
Joerg-Patrick Stübgen
Publication date
01-06-2011
Publisher
Springer-Verlag
Published in
Journal of Neurology / Issue 6/2011
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-011-5907-2

Other articles of this Issue 6/2011

Journal of Neurology 6/2011 Go to the issue

Letter to the Editors

A novel mutation of the SGCE-gene in a German family with myoclonus-dystonia syndrome

Original Communication

The effect of real and virtual visual cues on walking in Parkinson’s disease

Letter to the Editors

Acute pulmonary edema caused by a multiple sclerosis relapse

Letter to the Editors

Exploring the pathophysiology of Mal de Debarquement

Review

Teleneurology: is it really at a distance?

Original Communication

Migration and multiple sclerosis in immigrants to Australia from United Kingdom and Ireland: a reassessment. I. Risk of MS by age at immigration